Mirdametinib
Brand names: Gomekli · Active ingredient: Mirdametinib
In short: GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection .
What is Mirdametinib used for?
GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection .
Mirdametinib dosage
Prior to administration of GOMEKLI:
conduct comprehensive ophthalmic assessment .
assess ejection fraction (EF) by echocardiogram .
GOMEKLI is available in 2 dosage forms: capsules or tablets for oral suspension.
GOMEKLI capsules: must be swallowed whole, do not open, break or chew capsules.
GOMEKLI tablets for oral suspension: can be swallowed whole or can be dispersed in drinking water and administered orally as a liquid .
The recommended dosage of GOMEKLI is 2 mg/m2 orally twice daily (approximately every 12 hours) with or without food for the first 21 days of each 28-day cycle. The maximum dose is 4 mg twice daily. Continue treatment with GOMEKLI until disease progression or unacceptable toxicity. The recommended dose of GOMEKLI is based on body surface area (BSA) as shown in Table 1.
Body
Surface
Area
(m
2
)
* | Recommended
Dosage
for
Capsules
or Tablets for Oral Suspension
0.40 to 0.69 | 1 mg twice daily
0.70 to 1.04 | 2 mg twice daily
1.05 to 1.49 | 3 mg twice daily
≥1.50 | 4 mg twice daily
*The recommended dosage for patients with a BSA less than 0.40 m2 has not been established.
Missed
dose:
If the patient misses a dose of GOMEKLI, do not take an additional dose. Take the next scheduled dose at the prescribed time.
Vomiting:
If vomiting occurs after GOMEKLI administration, do not take an additional dose. Take the next scheduled dose at the prescribed time.
GOMEKLI
Capsules
Swallow GOMEKLI capsules whole with or without food. If more than one capsule is required for a dose, swallow one capsule at a time.
Do not open, break or chew capsules. Do not administer to patients who are unable to swallow a whole capsule .
GOMEKLI
Tablets
for
Oral
Suspension
GOMEKLI tablets for oral suspension can be swallowed whole with or without food. If more than one tablet is required for a dose, swallow one tablet at a time.
For patients who are not able to swallow whole tablets, prepare GOMEKLI tablets for oral suspension dispersed in drinking water and administer orally as a liquid .
Preparation
and
Administration
Add the prescribed number of tablets to a dosing cup containing approximately 5 mL to 10 mL of drinking water.
Gently swirl the water and tablets until the tablets are fully dispersed and an oral suspension is obtained. It takes approximately two to four minutes to fully disperse the tablets. Once the tablets are dispersed, the oral suspension will appear white and cloudy.
Administer the oral suspension immediately after preparation from a dosing cup or oral syringe.
After administration of the prepared suspension, add approximately 5 mL to 10 mL of drinking water to the dosing cup and gently swirl to resuspend any remaining particles. Administer the suspension to ensure the full dose is taken. …
How to take Mirdametinib — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (
Patient Information
and
Instructions for Use
).
Ocular
Toxicity
Advise patients and caregivers that GOMEKLI can cause serious ocular effects and to immediately contact their healthcare provider if they experience any changes in their vision .
Left
Ventricular
Dysfunction
Advise patients and caregivers that GOMEKLI can cause decreased LVEF and to immediately report any signs or symptoms of left ventricular dysfunction to their healthcare provider .
Dermatologic
Adverse
Reactions
Advise patients and caregivers that GOMEKLI can cause severe dermatologic adverse reactions and to contact their healthcare provider if they experience any skin reactions . Advise patients and caregivers that GOMEKLI can cause alopecia.
Embryo-Fetal
Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy .
Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with GOMEKLI and for 6 weeks after the last dose . …
Warnings & precautions
Do not take this medicine if: None.
GOMEKLI can cause ocular toxicity including retinal vein occlusion (RVO), retinal pigment epithelium detachment (RPED), and blurred vision.
In the pooled safety population , ocular toxicity occurred in 25% of patients treated with GOMEKLI: 20% were Grade 1 reactions, 3.8% were Grade 2 reactions, and 0.8% were Grade 3 reactions.
Adult
Patients
In the adult pooled safety population , ocular toxicity occurred in 28% of patients treated with GOMEKLI: 21% were Grade 1 reactions, 5% were Grade 2 reactions and 1.3% were Grade 3 reactions. Retinal vein occlusion (RVO) occurred in 2.7% of adult patients, including one Grade 3 reaction which required permanent discontinuation of GOMEKLI. RPED occurred in one adult patient (1.3%). Blurred vision occurred in 9% of adult patients treated with GOMEKLI.
Pediatric
Patients
In the pediatric pooled safety population ,
ocular toxicity occurred in 19% of patients: 17% were Grade 1 and 1.7% were Grade 2.
Conduct comprehensive ophthalmic assessments prior to initiating GOMEKLI, at regular intervals during treatment, and to evaluate any new or worsening visual changes such as blurred vision. Continue, withhold, reduce the dose, or permanently discontinue GOMEKLI as clinically indicated .
GOMEKLI can cause left ventricular dysfunction. Treatment with GOMEKLI has not been studied in patients with a history of clinically significant cardiac disease or LVEF <55% prior to initiation of treatment.
In the ReNeu study, in adult and pediatric patients , decreased LVEF of 10 to <20% occurred in 20%, and decreased LVEF of ≥20% occurred in 0.9% of patients treated with GOMEKLI. All patients with decreased LVEF were identified during routine echocardiography. Decreased LVEF resolved in 75% of these patients. …
Mirdametinib side effects
The following serious adverse reactions are described elsewhere in the labeling:
Ocular Toxicity
Left Ventricular Dysfunction
Dermatologic Adverse Reactions
Embryo-Fetal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to GOMEKLI in 133 patients (75 adults and 58 pediatric patients) in the ReNeu study (n=114) and Study NF-106 (n=19) [NCT-02096471].
Patients received GOMEKLI 2 mg/m2 orally twice daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Among 133 patients who received GOMEKLI, 62% were exposed for one year or longer, 38% were exposed for 2 years or longer, and 12% were exposed for 3 years or longer.
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
The safety of GOMEKLI was evaluated in the ReNeu study . Eligible patients were 2 years of age and older with neurofibromatosis type 1 (NF1) who had symptomatic plexiform neurofibromas (PN). …
About this medicine
GOMEKLI capsules and tablets for oral suspension contain mirdametinib, a kinase inhibitor. Mirdametinib is chemically known as (R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2- fluoro-4-iodophenyl)amino) benzamide. The molecular formula is C16H14 F3IN2O4 and the molecular weight is 482.20 g/mol. The structural formula for mirdametinib is:
Mirdametinib is a white to tan or pink solid with an aqueous solubility of 0.25 mg/mL and a pH of 7.2 in water at 25°C. The molecule has a pKa of 7.96.
GOMEKLI capsules and tablets for oral suspension are immediate release (IR) dosage forms intended for oral administration.
GOMEKLI (mirdametinib) 1 mg and 2 mg capsules contain 1 mg and 2 mg mirdametinib, respectively, in gelatin capsule and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The gelatin capsule shell contains FD&C blue #1, gelatin, titanium dioxide, and yellow iron oxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4c41bf90-5fa7-4935-a95c-e047ea6bbf8e. Read the full official label on DailyMed.